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Abstract
Background: Interaction of transmembrane mucins with the multivalent carbohydrate-binding protein galectin-3 is critical
to maintaining the integrity of the ocular surface epithelial glycocalyx. This study aimed to determine whether disruption of
galectin-3 multimerization and insertion of synthetic glycopolymers in the plasma membrane could be used to modulate
glycocalyx barrier function in corneal epithelial cells.
Methodology/Principal Findings: Abrogation of galectin-3 biosynthesis in multilayered cultures of human corneal
epithelial cells using siRNA, and in galectin-3 null mice, resulted in significant loss of corneal barrier function, as indicated by
increased permeability to the rose bengal diagnostic dye. Addition of b-lactose, a competitive carbohydrate inhibitor of
galectin-3 binding activity, to the cell culture system, transiently disrupted barrier function. In these experiments, treatment
with a dominant negative inhibitor of galectin-3 polymerization lacking the N-terminal domain, but not full-length galectin-
3, prevented the recovery of barrier function to basal levels. As determined by fluorescence microscopy, both cellobiose-
and lactose-containing glycopolymers incorporated into apical membranes of corneal epithelial cells, independently of the
chain length distribution of the densely glycosylated, polymeric backbones. Membrane incorporation of cellobiose
glycopolymers impaired barrier function in corneal epithelial cells, contrary to their lactose-containing counterparts, which
bound to galectin-3 in pull-down assays.
Conclusions/Significance: These results indicate that galectin-3 multimerization and surface recognition of lactosyl residues
is required to maintain glycocalyx barrier function at the ocular surface. Transient modification of galectin-3 binding could
be therapeutically used to enhance the efficiency of topical drug delivery.
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Introduction
The thick coat of carbohydrates in the glycocalyx that emerges
from apical membranes of epithelial cells is critical to maintaining
barrier function on mucosal surfaces. This glycocalyx is important
in preventing access of microbes to plasma membranes, but also
significantly restricts drug and vaccine targeting of epithelial cells
[1]. In the eye, the bioavailability of topical drugs is notoriously
poor, in the order of 5% or less [2,3]. Key reasons for such low
bioavailability include the short precorneal residence time of
ophthalmic solutions, as well as multiple permeability barriers
including the apical epithelial glycocalyx [2].
Glycocalyces on mucosal surfaces are rich in transmembrane
mucins, a group of high-molecular-weight glycoproteins with long
filamentous structures that extend 200–500 nm above the plasma
membrane—far above other glycoconjugates [4]. Stratified
human corneal and conjunctival epithelia express at least three
membrane-associated mucins: MUCs 1, 4, and 16 [5]. These large
molecules are characterized by the presence of heavily O-
glycosylated, central tandem repeats of amino acids, with their
carbohydrate component providing 50–90% of the mature
glycoprotein’s molecular mass [6]. The O-linked carbohydrates
play an important role in maintaining glycocalyx barrier function
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at the ocular surface by preventing apical adhesion and infection
[7,8,9].
A molecular mechanism by which mucin O-glycans contribute
to maintaining barrier function in the cornea is through
interaction with galectin-3 on the apical surface of epithelial cells
[10]. Galectins are a family of mammalian b-galactoside-binding
proteins that share highly conserved, carbohydrate-recognition
domains (CRDs). Galectin-3 is the exclusive member of the
chimera-type galectin subgroup that contains one CRD connected
to an extended non-lectin N-terminal domain [11]. As determined
by sedimentation velocity and equilibrium experiments, galectin-3
is predominantly monomeric in solution [12]. Moreover, it can
form homodimers by self-association through its CRDs in the
absence of its saccharide ligands [13]. However, in the presence of
its carbohydrate-binding ligands, galectin-3 can polymerize
through its N-terminal domain [13,14,15,16]. Multimerization of
galectin-3 often leads to cross-linking of its saccharide ligands and
formation of lattice-like structures on plasma membranes essential
for the biological activity of the cell [17,18,19].
Limited information is available on the precise organization of
the glycocalyx barrier in the most apical layer of the corneal
epithelium, and whether it can be transiently modified to allow
targeted delivery of ophthalmic drugs. The goal of this study was
to evaluate the role of the galectin-3 N-terminal polymerizing
domain in the modulation of corneal epithelial glycocalyx barrier
function, and to determine whether synthetic glycopolymers can
be anchored to corneal epithelial plasma membranes to interfere
with galectin-3 binding.
Results
Galectin-3 maintains corneal epithelial barrier function in
vitro and in vivo
To address the direct contribution of endogenous galectin-3 to
epithelial barrier function, galectin-3 expression was first tran-
siently abrogated in a three-dimensional culture system with
multilayered human cells using siRNA (Figure 1A). As shown by
western blot, transfecting human corneal-limbal epithelial (HCLE)
cells with galectin-3 siRNA twice—at 80% confluence and 3 days
post-confluence—reduced galectin-3 protein levels by 51618%
compared to scramble control (Figure 1B). In these experiments,
abrogation of galectin-3 did not alter the biosynthesis of either
galectin-8 or -9, two additional galectins expressed by the human
ocular surface epithelia [20] (Figure S1).
Next, we used the rose bengal diagnostic dye to determine the
effect of galectin-3 abrogation on epithelial barrier function. In this
assay, protection from rose bengal penetration into epithelial cells
is indicative of a fully functional mucosal barrier, whereas
penetration and positive staining of the epithelia indicates the
presence of a compromised glycocalyx barrier [10]. As shown in
Figure 1C, silencing of galectin-3 in human corneal epithelial cells
led to a statistically significant increase in dye uptake compared to
that of scramble control, indicating loss of barrier function after
galectin-3 abrogation.
To further evaluate the effect of galectin-3 on barrier function in
vivo, we examined the ocular surface of galectin-3 null mice. For
these experiments, whole eye globes were surgically removed and
incubated with a rose bengal solution for 60 seconds. Corneas of
galectin-3 null mice were characterized by a significant increase in
the number of punctate epithelial defects, corresponding to areas
of superficial epithelial cells with enhanced rose bengal staining, as
compared to those of wild type animals (Figure 2).
Disruption of galectin-3 binding and multimerization
impairs glycocalyx barrier function
We have previously reported that incubation of HCLE cells
with competitive carbohydrate inhibitors of galectin binding (b-
lactose or modified citrus pectin) impairs barrier function [10]. To
Figure 1. Galectin-3 maintains corneal epithelial barrier
function in vitro. (A) Timeline illustrating the transient abrogation of
galectin-3 in a three-dimensional culture system using siRNA. (B)
Analyses of whole corneal epithelial cell lysates revealed a 51618%
galectin-3 protein reduction in cultures treated with galectin-3 siRNA
(siGal3) as compared to scramble siRNA (siScr). Galectin-3 knockdown
did not affect expression of galectin-8 and -9. The upper panel shows
representative western blots. (C) The average area of rose bengal
staining after galectin-3 knockdown was 5169% higher than in
scramble cells. Representative images for each condition are shown in
the upper panel. Images were obtained using a 106objective lens. All
the experiments were performed at least in triplicate and represent the
mean 6SD. ***P,0.001.
doi:10.1371/journal.pone.0072304.g001
Figure 2. Abrogation of galectin-3 impairs barrier function in
mouse corneas. Numerical scoring for the intensity of staining with
rose bengal revealed a higher incidence of epithelial defects in corneas
of galectin-3 null mice (Gal-32/2) as compared to wild-type (Gal-3+/+)
controls. Representative images are shown in the left panel. *P,0.05.
doi:10.1371/journal.pone.0072304.g002
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gain insight into whether barrier function can be transiently
disrupted, HCLE cells were preincubated with b-lactose, followed
by incubation in basal medium for up to 6 hours. As previously
described, incubation with b-lactose, but not with the non-
inhibitory controls sucrose and maltose, resulted in a significant
increase in rose bengal uptake by the stratified cultures of corneal
epithelial cells (Figure 3A). Interestingly, removal of the b-lactose-
containing medium from the cell culture resulted in the recovery of
barrier function to basal levels within an hour, suggesting a
mechanism by which the cell-surface is repopulated by galectin-3
after competitive inhibition as previously described [21].
In additional experiments, we cloned and purified full-length
galectin-3 (rhGal3) and a galectin-3 mutant (rhGal3C) lacking the
N-terminal polymerization domain to determine whether galectin-
3 multimerization is necessary to provide glycocalyx barrier
function. As expected, incubation of corneal epithelial cell cultures
with rhGal3 for 1 hour at 4uC after treatment with b-lactose
allowed protection against rose bengal uptake (Figure 3B). In
contrast, addition of rhGal3C prevented recovery of barrier
function, indicating that galectin-3 multimerization is required to
maintain the integrity of the corneal epithelial glycocalyx.
Cellobiose glycopolymers incorporate into cell
membranes to modify glycocalyx integrity
The exogenous insertion of synthetic bioactive polymers is a
recently reported alternative approach to manipulating cell
surfaces in living cells [22]. Artificial mucin-like glycoconjugates
mimicking their natural counterparts have been designed by
adding carbohydrates to synthetically tractable polymer back-
bones. These large backbones are then linked to a terminal
hydrophobic phospholipid tail for anchoring into lipid bilayers
[23,24]. Here, we evaluated whether fluorescent glycopolymers
with a lipid anchor and chain-length distributions of 30 and 80 nm
(corresponding to 240 and 640 repeating units, respectively) could
be inserted into cultures of stratified human corneal epithelial cells
to modify the character of the cell surface. In these experiments,
two types of glycopolymers, featuring cellobiose- and lactose-
decorated polymeric backbones (Figure 4A), were used to establish
the relevance of lactosyl residues to barrier function.
As determined by fluorescence microscopy, cells treated with
glycopolymers showed cell surface fluorescence, independently of
the chain length distribution and carbohydrate content of their
polymeric backbones (Figure 4B). Incorporation was dependent on
the phospholipid tail, as control glycopolymers lacking this
hydrophobic domain showed no significant insertion into cells
(data not shown). Binding of lactose-containing glycopolymers, but
not their cellobiose counterparts, to recombinant human galectin-
3 was confirmed by pull-down assay (Figure 4C).
In subsequent experiments, we tested the effect of glycopolymer
insertion on barrier function using the rose bengal penetration
assay (Figure 5). Treatment of stratified corneal epithelial cells with
cellobiose-containing glycopolymers led to a significant increase in
rose bengal uptake, suggesting that surface insertion of cellobiose
residues with no affinity for galectin-3 disrupts the glycocalyx
barrier. On the other hand, treatment with lactose-containing
glycopolymers had no effect on rose bengal uptake as compared to
untreated cells.
Discussion
Maintenance of an effective epithelial barrier on exposed
mucosal surfaces requires both trans- and paracellular exclusion of
macromolecules and microorganisms. The intercellular tight
junction that connects individual epithelial cell membranes serves
as the rate-limiting paracellular barrier [25]. Transmembrane
Figure 3. Disruption of galectin-3 binding and multimerization impairs glycocalyx barrier function. (A) One-hour preincubation of
stratified human corneal epithelial cell cultures with b-lactose—but not with the non-inhibitory controls of galectin binding, sucrose and maltose—
resulted in a significant and transient increase in rose bengal uptake. (B) Incubation with rhGal3 after treatment with b-lactose allowed recovery of
barrier function in corneal epithelial cells. On the other hand, addition of rhGal3C resulted in sustained rose bengal uptake by the cell culture.
Representative images are shown in the left panel. Images were obtained using a 106objective lens. All the experiments were performed in triplicate
and represent the mean 6SD. ns, not significant, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0072304.g003
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mucins and their associated O-glycans, on the other hand,
maintain the integrity of the epithelial glycocalyx and provide a
transcellular barrier to particles and pathogens [26,27,28]. While
functioning as a protective mechanism to exposed surfaces, this
resistance to apical internalization also impairs the delivery of
therapeutic formulations into mucosal surfaces. Overcoming these
barriers in a transient manner is, therefore, an alternative
approach to efficiently improving drug entry from topical
administration.
Through studies performed during the last decade, it has
become apparent that transmembrane mucins bind galectins in a
carbohydrate-dependent manner to elicit a variety of biological
functions under both physiological and pathological conditions
[10,29,30]. In human corneal epithelial cells, competitive inhibi-
tion of galectin binding and abrogation of c1galt1—a critical
galactosyltransferase required for the synthesis of core 1 mucin O-
glycans—has been associated with loss of barrier function [10,31].
In addition to galectin-3, several members of the galectin family,
such as galectins -8 and -9 [20,32] and galectins -1 and -7 [33],
have been detected in human and mouse ocular surface epithelial
cells, respectively. In our experiments, selective abrogation of
galectin-3 biosynthesis in vitro and in vivo resulted in increased
permeability to the rose bengal diagnostic dye (Figures 1,2),
indicating a role for this galectin in maintaining glycocalyx barrier
function. Interestingly, lack of galectin-3 did not lead to complete
abrogation of barrier function, suggesting that other carbohydrate-
binding proteins may contribute to maintaining the integrity of the
epithelial glycocalyx. Evidence indicates that multiple members of
the galectin family can recognize mucin-type O-glycans as
biological counter-receptors on cell surfaces [30,34,35], supporting
the possibility of a redundant function for these proteins in
maintaining barrier function at the ocular surface.
In addition to its carbohydrate recognition domain, the
biological function of galectin-3 is also regulated by the non-lectin
N-terminus. This region not only mediates multimerization, but
also shows positive cooperativity in lectin binding to immobilized
ligand clusters [15,36]. In our experiments, short-term addition of
a competitive inhibitor of galectin binding resulted in transient
disruption and subsequent recovery of barrier function (Figure 3).
This result suggests a mechanism, previously shown in SUDHL-6
cells [21], by which the cell-surface is repopulated by galectin-3
soon after removal of the inhibitor from the cell culture. The
recovery of barrier function, however, was impaired in the
presence of rhGal3C, a galectin-3 mutant lacking the N-terminal
domain, indicating that disruption of galectin-3 multimerization
during the recovery process impairs barrier function. Interestingly,
Figure 4. Synthetic glycopolymers incorporate into stratified cultures of human corneal epithelial cells. (A) Schematic structure and
properties of Alexa Fluor 488 cellobiose- and lactose-containing glycopolymers functionalized with a phospholipid end group. (B) Fluorescence
microscopy images demonstrated that, following a 1-hour incubation, glycopolymers (green) with 240 and 640 repeating units incorporated into
islands of stratified corneal epithelial cells. DAPI was included in the mounting medium to localize the position of the nuclei (blue) in the cell culture.
Images were obtained using a 406 objective lens. (C) By pull-down assay, synthetic glycopolymers with lactose-decorated backbones, but not
cellobiose derivatives, bound to an rhGal3 affinity column.
doi:10.1371/journal.pone.0072304.g004
Figure 5. Cellobiose glycopolymers impair glycocalyx barrier
function in human corneal epithelial cells. As determined using
the rose bengal penetration assay, treatment of stratified corneal
epithelial cells for 1 hour with cellobiose glycopolymers, containing
either 240 or 640 repeating units, significantly impaired glycocalyx
barrier function. No effect on rose bengal uptake was observed when
lactose-containing glycopolymers were used. Images were obtained
using a 106 objective lens. All the experiments were performed in
triplicate and represent the mean 6SD. ns, not significant; ***P,0.001.
doi:10.1371/journal.pone.0072304.g005
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the galectin-3 N-terminal domain can be proteolytically cleaved by
matrix metalloproteinases (MMPs), particularly MMP2 and
MMP9 [19]. As increased levels of MMPs are commonly
associated with ocular surface disease [37,38], we speculate that
proteolytic cleavage of galectin-3 under pathological conditions
may contribute to the increased uptake of rose bengal and loss of
barrier function commonly observed in these patients.
Identifying the factors that facilitate or hinder association
between galectins and transmembrane mucins is not only critical
to understanding the organization of the epithelial glycocalyx, but
also may be exploited for potential therapeutic development.
Synthetic glycopolymers that emulate natural mucins have been
developed during the past few years to study how the structure of
mucin glycans and their spatial arrangements along the mucin’s
polypeptide backbone affect the interactions with carbohydrate-
binding proteins [39,40]. Glycopolymers functionalized with lipid
tails have been introduced into membranes of live cells such as
ldlD CHO, a cell type lacking endogenous mucins [23]. Here, we
show that glycopolymers decorated with pendant cellobiose- and
lactose-glycans incorporate into cultures of stratified human
corneal epithelial cells (Figure 4), known to contain apical islands
of undifferentiated and differentiated cells, the latter featuring
glycosylated transmembrane mucins [41,42]. Increasing the
amount of cellobiose on the cell surface via glycopolymer insertion
enhanced rose bengal uptake (Figure 5), suggesting that interfer-
ence with surface recognition of endogenous lactosyl residues
impairs barrier function at the ocular surface. Unexpectedly,
insertion of lactose-containing glycopolymers, which have the
capacity to bind galectin-3, did not enhance barrier function in
our three-dimensional culture system; in fact, the regions of rose
bengal uptake detected were similar to those of control cultures. A
possible explanation is that lactose-containing glycopolymers
incorporate into the glycocalyx but fail to compete for galectin-3
binding in the presence of endogenous glycosylated mucins—
natural ligands for galectin-3 on apical surfaces [10,30]. Alterna-
tively, lactose-containing glycopolymers may incorporate into
undifferentiated apical cells with poorly glycosylated mucins, but
in insufficient quantities to efficiently induce lattice formation. As
restoring barrier function is essential to the treatment of ocular
surface disease, further research is required to elucidate the
underlying causes that may impair the gain of glycocalyx barrier
function when synthetic glycopolymers are used.
Overall, data in this study indicate that both multimerization of
galectin-3 and surface recognition of lactosyl residues are required
to maintain glycocalyx barrier function at the ocular surface.
Studies aiming to determine whether the ocular surface glycocalyx
can be manipulated therapeutically to enhance bioavailability of
topical drugs are likely to lead to greatly improved treatment for
ocular surface diseases.
Methods
Ethics Statement
All animal procedures in this study were performed in
accordance with the Association for Research in Vision and
Ophthalmology Resolution on the Use of Animals in Vision
Research, the recommendations of the National Institutes of
Health Guide for the Care and Use of Laboratory Animals, and
approved by Tufts University Division of Laboratory Animal
Medicine in Boston, MA; Protocol # B2011-15. The techniques
used for the development of the human corneal-limbal epithelial
cell line (kindly provided by Dr. Ilene Gipson; Schepens Eye
Research Institute; Boston, MA) have been previously described
[41].
Mice
Galectin-3 null (Gal32/2) mice were generated by homologous
recombination on a C57BL/6 background as described previously
[43]. Six- to eight-week-old, Gal32/2 and wild type mice (14 and
12 animals per group, respectively) were used.
Cell culture
Telomerase-immortalized human corneal-limbal epithelial
(HCLE) cells were plated at a seeding density of 56104 cells/
cm2. HCLE cells were maintained at 37uC in 5% CO2 and grown
in GIBCO keratinocyte serum-free medium (KFSM) supplement-
ed with bovine pituitary extract, 0.2 ng/ml epithelium growth
factor (EGF) and 0.4 mM CaCl2. Once confluent, cells were
switched to Dulbecco’s modified Eagle’s medium/F-12 (DMEM/
F12) supplemented with 10% calf serum and 10 ng/ml EGF for 7
days to promote cell stratification and establishment of barrier
function [42].
Cloning and purification of full-length galectin-3 and
galectin-3 N-terminal deletion mutant
cDNA encoding human galectin-3 (LGALS3, Accession No. -
BAA22164.1) was amplified by polymerase chain reaction (PCR)
using reverse transcribed mRNA extracted from HCLE cells. The
amplification was performed in a 20-ml reaction volume containing
2 ml of desalted cDNA, 200 mM dNTP, 0.5 mM of 59 and 39
primer, and 1 unit of PhusionH high-fidelity DNA polymerase
(New England Biolabs, Ipswich, MA) in 1x PhusionH HF buffer.
The 59 and 39 primer sequences containing NdeI and BamHI
cloning sites (bolded) were, respectively, 59-GGCGGCGG-
CGGCTCTAGACATATGGCAGACAATTTTTCGCTCCAT-
GATGC-39 (primer 1) and 59-GGCGGCGGCGGCGGATC-
CGCTCTTCCGCATTATATCATGGTATATGAAGCACT-39
(primer 2). The samples were placed in a MyCyclerTM Thermal
Cycler (Bio-Rad Laboratories Inc.; Hercules, CA) programmed for
a temperature-step cycle of 98uC (30 seconds) and 72uC (40
seconds) for 25 cycles. After the final cycle, the reaction was
maintained at 72uC for 10 minutes. The final reaction products
were resolved on a 0.75% agarose gel containing ethidium
bromide (0.5 mg/ml) (Figure S2A). The PCR product was cloned
into a pTWIN2 vector (New England Biolabs) by restriction
endonuclease digestion using NdeI and BamHI (New England
Biolabs). rhGal3C, a truncated form of galectin-3 lacking the first
62 amino acids in the N-terminal polymerizing domain, was
generated from the pHGal3 plasmid using the PhusionTM Site-
Directed Mutagenesis Kit (New England Biolabs) (Figure S2B).
The 59 and 39 phosphorylated primers were, respectively, 59Phos-
TACCCTGGAGCACCTGG-39 (primer 3) and 59Phos-CAT-
ATGTATATCTCCTTCTTAAAGTTAAACA-39 (primer 4).
The sample was placed in a MyCyclerTMprogrammed for a
temperature-step cycle of 98uC (30 seconds) and 72uC (2 minutes)
for 25 cycles. After the final cycle, the reaction was maintained at
72uC for 10 minutes. The PCR product was resolved in an agarose
gel for size verification and DNA quantification, and then ligated.
Plasmids were sequenced at the DNA Core Facility, Massachusetts
General Hospital, Boston, MA.
Both expression constructs were transformed into E. coli
RosettaTM cells (Novagen, Madison, WI). Positive transformants
were selected in agar plates and grown at 37uC with shaking in LB
medium (10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, 1 g/l
dextrose, and 1 g/l MgCl2, pH 7.2) supplemented with ampicillin
(100 mg/mL) and chloramphenicol (34 mg/ml) to an OD600 of
0.5–0.8. Heterologous protein expression was induced by the
addition of 0.3 mM IPTG (American Bioanalytical, Inc.; Natick,
Galectin-3 in Glycocalyx Barrier Function
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MA), and the induced cultures incubated at 15uC overnight with
shaking. Bacterial cultures were then centrifuged at 10,0006g for
10 minutes at 4uC, and the supernatant discarded. Bacterial pellets
were resuspended in lysis buffer (20 mM Tris, pH 8.0, 5 mM
EDTA, 10 mM sucrose, 20 mM b-mercaptoethanol) and sonicat-
ed at 4uC, over three 60-second cycles, separated by 1-minute
intervals. Lysates were then clarified at 10,0006g for 20 minutes
and used immediately.
rhGal3 and rhGal3 C were purified from lysates by affinity
chromatography using lactosyl sepharose as described previously
[44]. Protein content in elution fractions was determined using the
BCA Protein Assay Kit (Pierce; Rockford, lL). Aliquots (10 ml)
were run on a 10% SDS-PAGE gel and analyzed by GelCodeH
Blue Stain (Thermo Fisher Scientific; Rockford, IL) to assess the
purity of the protein preparation. Fractions enriched in recombi-
nant protein were pooled, and the identity of the purified
recombinant protein further confirmed by immunoblot (Figure
S2) as described below. To eliminate contaminating bacterial
endotoxins, rhGal3 and rhGal3 C were further purified by
polymyxinB affinity chromatography (Sigma-Aldrich; St. Louis
MO). The absence of lipopolysaccharide was confirmed using
ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit (Gen-
Script; Piscataway, NJ) following the manufacturer’s instructions.
Protein solutions were concentrated by filtration using a Vivaspin
20 centrifugal concentrator (10 kDa molecular weight cut-off; GE
Healthcare; Littleton, MA), dialyzed against PBS buffer containing
10% of glycerol, and stored at 220uC.
Galectin-3 siRNA transfection
Galectin-3 was depleted using SilencerH Select Pre-designed
siRNA (S8149; Ambion, Austin; TX, USA) targeting human
LGALS3 mRNA. HCLE cells were transfected in 6-well culture
plates twice, once at 80% confluence and then 3 days post-
confluence, with galectin-3 siRNA or scramble control. For each
transfection, cells were treated with 500 nM siRNA in Opti-
MEMH reduced-serum medium GlutaMAXTM (Invitrogen; Carls-
bad, CA, USA) containing 1 ml/100 mm2 LipofectamineTM 2000
(Invitrogen) for 6 hours. Cultures were then incubated for
20 hours with either KSFM, for cells treated at 80% confluence,
or DMEM, for stratifying cells. After the final transfection, the
media was switched to DMEM/F-12 to promote stratification and
differentiation.
Glycopolymer synthesis
Synthetic glycopolymers were prepared by condensation of b–
aminooxylactose or b–aminooxycellobiose to poly(methylvinyl
ketone) backbones monofunctionalized with Alexa Fluor 488
and endowed with a phospholipid tail for anchoring to cell
membranes. The synthesis of the polymer backbone precursors
with narrow chain-length distributions has been previously
described in detail [45]. The synthetic glycopolymers accommo-
date extended conformations and insert into lipid bilayers, where
they are fluid and project away from the surface [45]. The
aminooxy-glycans were prepared according to published proce-
dures [46].
The glycopolymers used in this study were prepared according
to the following general procedure: AF488-labeled poly(methylvi-
nyl ketone) backbones (1.0 mg, 0.014 mmol of keto groups) were
dissolved in tetrahydrofurane (95 ml) and transferred into a 4 ml
glass vial containing a solution of b-aminooxy-glycan (6.1 mg,
0.017 mmol, 1.2 equiv per ketone group) in sodium acetate buffer
(95 ml, 100 mM, pH=5.2). The vials were placed in a heating
block set at 50uC and heated for 12 hours. Next, the solvents were
removed and additional acetate buffer (100 ml) was added. The
tubes were heated at 50uC for an additional 18 hours. The crude
reaction mixtures were then loaded onto a Sephadex G-25 (PD-
10) desalting column. The polymers were eluted with DI water,
and the collected fractions were lyophilized to give orange
glycopolymers in .90% isolated yield. Based on 1H NMR
analysis, approximately 62–65% of the pendant keto groups in the
resulting glycopolymers were conjugated with a glycan. 1H NMR
spectra of all polymers were collected in D2O on a Bruker Biospin
Advance II, 500 MHz, High Performance NMR spectrometer
with multinuclear CP-MAS probe and results are included in
Supporting Information (Figure S3). Specifications for individual
glycopolymers are as follows:
Cell240: repeating units, n, = 240, cellobiose content = 62% n,
Mw=69 kDa, isolated yield = 3.7 mg (100%), estimated length, l,
,30 nm.
Cell640: repeating units, n, = 640, cellobiose content = 65% n,
Mw=189 kDa, isolated yield = 3.8 mg (93%), estimated length, l,
,80 nm.
Lac240: repeating units, n, = 240, lactose content = 62% n,
Mw=69 kDa, isolated yield = 3.7 mg (100%), estimated length, l,
,30 nm.
Lac640: repeating units, n, = 640, lactose content = 62% n,
Mw=181 kDa isolated yield = 4.0 mg (100%), estimated length,
l, ,80 nm.
For HCLE cell labeling, glycopolymers were dissolved in PBS.
Serum-starved, stratified corneal epithelial cells were incubated
with 2 mM glycopolymers for 1 hour at room temperature.
Rose bengal uptake
Barrier function in cell culture was assayed by a 5-minute
incubation with 0.1% rose bengal dye (Acros Organics; Morris
Plains, New Jersey) as described previously [47]. For rose bengal in
vitro assay, HCLE cells were serum-starved for 2 hours, then
treated with serum-free DMEM/F12 medium supplemented with
0.1 M disaccharides (b-lactose, sucrose or maltose), rhGal3 or
rhGal3C (100 mg/ml), and lactose- or cellobiose-containing
glycopolymers (2 mM). The extent of dye penetrance in cell
culture was assessed using an inverted microscope (Nikon Eclipse
TS100). Pictures were taken at 106 with a SPOT Insight Fire
Wire Camera (Diagnostic Instruments, Inc.; Sterling Heights, MI).
Images were processed further for dye penetrance quantification
using ImageJ software (NIH, Bethesda, MD). Uptake is repre-
sented as the integrated density of stained areas, and is normalized
to control conditions.
For barrier function analysis in vivo, mice were euthanized and
whole eye globes removed surgically, as described previously [48],
by an ophthalmologist who was masked to the type of mice.
Enucleation was performed by gently holding the eyeball on its
side with forceps, without touching the cornea, and cutting the
optic nerve with curved scissors at a distance of about 2 mm from
the eyeball. The whole globes were then pinned through the sclera
to a culture dish using Minutien pins, and immediately embedded
in PBS, pH 7.4, containing 0.1% rose bengal. The corneas were
facing up during the entire procedure and care was taken to avoid
any contact with them. After 60 seconds, the corneas were washed
with PBS using a 1 ml plastic disposable pipette. Immediately
thereafter, a second observer obtained digital images of the
corneas by placing the eyes under a stereomicroscope with double
gooseneck light sources and equipped with a 12 megapixel digital
camera. The masked digital images were then sent in a random
fashion to four independent observers who were instructed to score
rose bengal corneal staining from 0 (none) to 5 (entire corneal
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surface) based on the surface area stained. After the results of the
staining scores were provided, the blinding codes were broken, and
results were matched to the type of mice, to perform statistical
analysis.
Immunoblotting
HCLE protein extracts in RIPA buffer were electrophoresed on
10% SDS-PAGE gels and transferred onto nitrocellulose mem-
branes (Biorad; Hercules, CA). Membranes were then blocked
with 5% Blotto (Biorad) in TBST for 1 hour at room temperature,
followed by incubation overnight at 4uC with the following
primary antibodies: anti-galectin-3 (H160; 1:3,000; Santa Cruz
Biotechnology; Santa Cruz, CA), anti-galectin-8 (D-18; 1:3,000;
Santa Cruz Biotechnology), anti-galectin-9 (C-20; 1:3,000; Santa
Cruz Biotechnology) and anti-GAPDH. Following incubation with
the corresponding peroxidase-conjugated secondary antibody
(1:5,000; Santa Cruz), positive binding was visualized with
chemiluminescence (SuperSignal West Pico substrate; Thermo
Scientific) on HyBlot CL autoradiography film (Denville Scientific;
Inc., Metuchen, NJ). Immunoblots were quantified using ImageJH
software (National Institutes of Health; Bethesda, MD).
Galectin-3 affinity chromatography
An rhGal3 affinity column was prepared by coupling 5 mg of
rhGal3 to cyanogen bromide-activated Sepharose 4B (GE
Healthcare; Piscataway, NJ) according to manufacturer’s instruc-
tions. Binding activity of rhGal3 conjugated to beads was assessed
by pull-down of asialofetuin (Sigma-Aldrich) [49]. Fifty microliters
of rhGal3 beads were incubated with 200 mg of asialofetuin with
or without 0.1 M b-lactose, for 1 hour, at room temperature.
Beads were washed 5 times with PBS before addition of SDS-
PAGE sample buffer. After boiling for 5 minutes at 90uC, beads
were centrifuged, and supernatant run on a 10% SDS-PAGE gel.
Protein was analyzed by GelCodeH Blue Stain.
For the pull-down assay, a 1 ml solution of 200 mM glycopo-
lymers in PBS were incubated with 100 ml rhGal3-conjugated
agarose beads for 1 hour at room temperature. Beads were
washed 3 times with PBS to remove unbound glycopolymers and
mounted on glass slides.
Fluorescence microscopy
HCLE cells grown on culture chamber slides (Lab-Tek;
Naperville, IL, USA) were rinsed in PBS and fixed in methanol
at 220uC for 5 minutes. Slides were washed multiple times with
PBS, mounted using Vectashield mounting medium with DAPI
(Vector Laboratories; Burlingame, CA), and photographed using a
fluorescence microscope (Nikon Eclipse E-800; Tokyo, Japan).
Beads were mounted using Vectashield medium (Vector Labora-
tories) and covered with coverslips.
Supporting Information
Figure S1 Galectin expression at the human ocular
surface. As shown by glycogene microarray analysis, galectin-3 is
the most predominant galectin detected in impression cytology
samples of human conjunctival epithelium (detailed data on
glycogene expression can be found at http://www.functional
glycomics.org/glycomics/publicdata/microarray.jsp; Accession #
MAEXP_272_042605).
(TIF)
Figure S2 Cloning strategy for the generation of full-
length galectin-3 and a galectin-3 N-terminal deletion
mutant. (A) Galectin-3 mRNA extracted from HCLE cells was
reverse transcribed, amplified by PCR, and cloned into a pTWIN2
vector using NdeI and BamHI. A 0.8-kb PCR product correspond-
ing to full-length galectin-3 was detected by agarose-gel electro-
phoresis. The pHGal3 plasmid was transformed into E. coli
RosettaTM cells and the protein lysates purified by affinity
chromatography. (B) A truncated form of galectin-3 lacking the
first 62 amino acids in the N-terminal domain was obtained by site-
directed mutagenesis. The identity of the purified recombinant
proteins was confirmed by immunoblot. CRD, carbohydrate
recognition domain; PGR, proline, glycine, and tyrosine-rich
domain.
(TIF)
Figure S3 1H NMR spectra of synthetic glycopolymers
used in this study.
(TIF)
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